Autonomix Medical
Develops transvascular catheters to sense, target, and ablate peripheral nerves.
Something off on this page? Send us feedback.
Profile
Develops a pre-commercial transvascular catheter system intended to sense, map, ablate, and verify peripheral-nerve targets. It plans procedure-based revenue from single-use catheters, a generator, and software, but its proprietary sensing catheter remains a hand-built prototype requiring validation and FDA review.
Develops a transvascular catheter platform intended to find faint peripheral-nerve signals, apply radiofrequency energy to selected nerve tissue, and verify whether signals have been interrupted. Its lead human program targets pancreatic-cancer pain, while a standalone sensing program for renal denervation remains preclinical.
Plans procedure-based revenue from single-use sensing and ablation catheters sold to hospital catheterization laboratories, alongside a generator and software interface. Production is outsourced, and it has no product clearance, commercial sales, or operating revenue.
Depends on engineering and clinical validation of its proprietary devices, FDA review, financing, a single lead-device manufacturer, and eventual reimbursement. The sensing catheter remains a hand-built prototype not cleared for human use.
Company facts
Key statistics
Year to date −53.1% · Average volume (30d) 9.2M
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 12, 2026Q1 FY27 | −$6.40 | −$5.02 | +21.6% | — | — | — | −17.32% |
| Jun 4, 2026Q4 FY26 | −$4.83 | −$4.83 | 0.0% | — | — | — | +0.94% |
| May 27, 2026Q4 FY26 | −$0.23 | −$0.23 | 0.0% | — | — | — | −0.57% |
| Feb 11, 2026Q3 FY26 | −$0.36 | −$0.36 | 0.0% | — | — | — | −1.72% |
Financial highlights
| 12 quarters | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $0 | $0 | $0 | $0 | −$3.0K | $0 | |
| Operating income | −$3.3M | −$3.4M | −$7.5M | −$3.3M | −$2.7M | −$2.8M | |
| Net income | −$3.2M | −$3.3M | −$7.5M | −$3.3M | −$2.7M | −$2.7M | |
| Diluted EPS | −$26.84 | −$22.57 | −$28.91 | −$7.65 | −$4.91 | −$5.02 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY23 $0 · FY24 $0 · FY25 $0 · FY26 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $3.5M · Total debt $0 · Total assets $4.0M · Shareholders' equity $3.2M
Dividends
No dividends on record.
Ownership
Shares outstanding 543.0K · Float 526.4K · 97.0% free float
Insiders — no current Form 4 position.
Insider tradesForm 4
Nothing filed in the last 12 months.
View detailsPeers
- Medtronic
Direct renal-denervation rival with RF catheter and generator.
- Johnson & Johnson
Integrated mapping and ablation platform rival in catheter labs.
- Abbott
EP mapping and RF-ablation system rival in hospital labs.
- Boston Scientific
Large EP ablation rival with a scaled catheter-lab platform.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Autonomix Medical | $5.18 | −1.99% | $2.9M | — | — | — | — |
| Medtronic | $91.58 | +0.42% | $116.78B | 24.5 | 15.3 | 3.2 | +9.9% |
| Johnson & Johnson | $268.40 | +0.13% | $645.95B | 31.1 | 22.4 | 6.6 | +6.6% |
| Abbott | $112.20 | −0.22% | $194.62B | 36.2 | 19.4 | 4.2 | +13.0% |
| Boston Scientific | $46.85 | +0.03% | $69.62B | 19.0 | 14.2 | 3.3 | +7.5% |
| Median | 27.8 | 17.3 | 3.7 | +8.7% |